Adicet Bio ( ($ACET) ) has issued an update. On December 19, 2025, Adicet Bio’s shareholders approved, and its board subsequently set, a 1-for-16 ...

Investing.com -- Adicet Bio Inc (NASDAQ:ACET) stock fell 9.2% in premarket trading Friday after the clinical-stage biotechnology company announced a 1-for-16 reverse stock split to regain compliance ...

KALA BIO ( ($KALA) ) has shared an update. On December 19, 2025, six directors of KALA BIO—Marjan Farid, M.D., Andrew I. Koven, C. Daniel Myers, ...

Techne’s weak performance relative to the healthcare sector over the past year, Wall Street analysts remain strongly ...

Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ...

Passage Bio, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-20, effective July 14, 2025, in order to meet Nasdaq's minimum bid price requirement of $1.00 per share. The ...

Nuvation Bio stock has been on a roll since late October, as the shares have roughly tripled since then. The main driver of this rally is the potentially transformative acquisition of AnHeart ...

Bluebird Bio has launched three gene-editing therapies. These treatments are expensive and complex to administer, and they face stiff competition. Though Bluebird Bio is an innovative biotech, the ...

Indeed, Climb Bio (NASDAQ:CLYM) stock is up 135% in the last year, providing strong gains for shareholders. But while history lauds those rare successes, those that fail are often forgotten; who ...

Bio-Path says the first patient treated with a higher dose in Phase 1/1b study of BP1001-A has shown tumor regression and stable disease. Bio-Path reports its second-quarter financial results last ...

If a little bird told you to think about buying Bluebird Bio (NASDAQ: BLUE) stock recently, there's a lot of information you'll need to evaluate. Between the new product that this small biotech has ...